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Summary
 
The crystal structure of the human class I major histocompatibility complex molecule, human
histocompatibility leukocyte antigen (HLA)-Cw4, the ligand for a natural killer (NK) cell
inhibitory receptor, has been determined, complexed with a nonameric consensus peptide
(QYDDAVYKL). Relative to HLA-A2, the peptide binding groove is widened around the
 
COOH terminus of the 
 
a
 
1 helix, which contains residues that determine the specificity of
HLA-Cw4 for the inhibitory NK receptor, KIR2D. The structure reveals an unusual pattern
of internal hydrogen bonding among peptide residues. The peptide is anchored in four speci-
ficity pockets in the cleft and secured by extensive hydrogen bonds between the peptide main
chain and the cleft. The surface of HLA-Cw4 has electrostatic complementarity to the surface
of the NK cell inhibitory receptor KIR2D.
Key words: HLA-Cw4 • crystal structure • killer cell inhibitory receptor • natural killer cell 
recognition • autoimmunity
 
C
 
lass I MHC molecules in both humans and mice me-
diate target cell recognition by CTLs and NK cells. In
humans, class I MHC heavy chains are encoded by three
gene loci, HLA-A, -B, and -C. HLA-A and -B molecules are
expressed abundantly on the cell surface; they are primarily
responsible for presenting viral or tumor antigens to CD8
 
1
 
CTLs. Structures of HLA-A and -B molecules bound to a
single peptide or a mixture of peptides have demonstrated
that the sequence and conformation of the peptide largely
determines the antigenic identity of the peptide–MHC com-
plex (for review see references 1 and 2). HLA-C is expressed
at much lower levels on the cell surface and presents antigens
less efficiently than HLA-A and -B (3). Although an HLA-
Cw4–restricted CTL clone that recognizes a highly con-
served region of human HIV-1 gp120 (4) and a CD8
 
1
 
HIV-1 gag-specific T lymphocyte clone that is restricted by
HLA-Cw3 (5) have been described, HLA-C molecules are
more restricted in their peptide binding than HLA-A and
-B alleles (6). HLA-C alleles are associated with susceptibil-
ity to autoimmune diseases (3); increased frequency of HLA-
Cw4, for example, correlates with the occurrence of type 2
diabetes (7). HLA-Cw4 is also associated with the rapid pro-
gression of AIDS (8). One of the major functions of HLA-C
molecules lies in NK cell recognition.
Human inhibitory NK cell receptors specifically recog-
nize class I MHC molecules on target cell surfaces and de-
liver an inhibitory signal that prevents target cell lysis by
NK cells (for review see references 9 and 10). Killer cell Ig-
like receptors (KIRs)
 
1
 
 on NK cells have been identified for
polymorphic HLA-B and -C molecules (11–13). KIR2D
molecules (KIRs with two Ig-like domains, also referred to
as p58 and p50) are involved in the recognition of HLA-C
and distinguish the polymorphism at positions 77 and 80 of
the HLA-C heavy chain (14). HLA-Cw4 and related alleles
(HLA-Cw2, -Cw5, and -Cw6) have Asn77 and Lys80 and
are recognized by KIR reactive with the EB6 (15) or
HP-3E4 (16) antibody (e.g., KIR2DL1). HLA-Cw3 and
related alleles (HLA-Cw1, -Cw7, and -Cw8) contain Ser77
and Asn80 and interact with KIR that are reactive with the
GL183 antibody (15) (e.g, KIR2DL2). The structure of the
HLA-Cw4–specific KIR2DL1 (originally named p58-cl42
KIR) has been recently determined (17); it consists of two
Ig-like domains positioned at an acute 60
 
8
 
 angle. Residues
at the domain elbow of KIR2DL1 have been identified as
important for HLA-Cw4 binding (18–20).
In this study, we present the structure of HLA-Cw4
 
(Cw
 
*
 
0401; Protein Data Bank accession code 1QQD),
which specifically interacts with KIR2DL1. The conforma-
tion of the nonameric peptide bound to HLA-Cw4 is stabi-
lized by the internal hydrogen bonding among peptide resi-
 
1
 
Abbreviations used in this paper:
 
 KIRs, killer cell Ig-like receptors; PEG,
polyethylene glycol; rms, root mean square. 
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dues. The peptide side chains fit into four specificity pockets,
and extensive hydrogen bonds form between peptide main
chain atoms and the MHC heavy chain along the peptide.
Relative to HLA-A2, the peptide binding groove of HLA-
Cw4 is widened at the COOH-terminal portion of the 
 
a
 
1
helix (up to 2.4 Å), and the adjacent loop region (residues
A14–20) protrudes up and toward the 
 
a
 
1 helix (up to 4.2
Å). The COOH terminus of the 
 
a
 
1 helix forms a potential
KIR binding site on HLA-Cw4 and is analyzed in light of
the receptor and peptide–MHC ligand structures.
 
Materials and Methods
 
Protein Purification and Crystallization.
 
The HLA-Cw4 heavy
chain (residues A1–275) was overexpressed in the 
 
Escherichia coli
 
strain BL21 (DE3) pLysS and purified as insoluble inclusion body
protein (21). 
 
b
 
2
 
m (microglobulin) inclusion body was produced
in the 
 
E
 
.
 
 coli
 
 strain XA90 as described (22). The HLA-Cw4
heavy chain and 
 
b
 
2
 
m were reconstituted in the presence of the
peptide, QYDDAVYKL, and the refolded complex was purified
by gel filtration chromatography (21). Refolded HLA-Cw4 crys-
tallized in 18% polyethylene glycol (PEG) 8000, 0.2 M Ca ace-
tate, and 0.1 M Na cacodylate, pH 6.5. The crystals obtained ini-
tially were thin plates and were improved by streak seeding using
12% PEG 8000, 0.2 M Ca acetate, and 0.1 M Na cacodylate, pH
6.5, as the reservoir solution. The space group is P2
 
1
 
2
 
1
 
2
 
1
 
, with
one molecule per asymmetric unit, and unit cell parameters a
 
 5
 
54.96 Å, b
 
 5 
 
77.49 Å, and c
 
 5 
 
108.59 Å.
 
Data Collection.
 
The crystals were stabilized in a harvesting
solution (22.5% PEG 8000, 0.2 M Ca acetate, and 0.1 M Na ca-
codylate, pH 6.5) for 2 h and then soaked in a cryoprotectant-
containing solution (22.5% PEG 8000, 0.2 M Ca acetate, 0.1 M
Na cacodylate, pH 6.5, and 25% glycerol) for 5 min before being
flash-cooled with liquid nitrogen. X-ray diffraction data were
collected to 2.9 Å with the ADSC 1K CCD detector at A-1
beamline of the Cornell High Energy Synchrotron Source (CHESS;
Ithaca, NY). The diffraction was anisotropic, and the mosaicity of
the crystal varied from 0.5 to 1.5
 
8
 
 depending on the orientation
of the crystal. Data were integrated and scaled (Table I) using
DENZO and SCALEPACK (HKL Research).
 
Molecular Replacement and Refinement.
 
The HLA-Cw4 struc-
ture was determined by molecular replacement using the pro-
gram AMoRe (23). Except for the peptide, the HLA-B27 mole-
cule (Protein Data Bank [Brookhaven National Laboratory,
Upton, NY] accession code 1HSA; reference 24) was used as the
search model. Rotation and translation function searches using all
data from 8 to 4 Å yielded a clear solution with a correlation co-
efficient of 44.9% and R factor of 44.4% (the next highest peak
has a correlation coefficient of 26.7% and R factor of 51.0%).
The molecular replacement solution was used as the starting
model for refinement, with residues that differ between HLA-
Cw4 and HLA-B27 (34 total residues in the heavy chain) replaced
by alanines and the peptide excluded. All data from 22 to 2.9 Å,
with |Fo| 
 
. 
 
0, were included for refinement; 10% of the reflec-
tions were omitted for the calculation of R
 
free
 
. The model was
subjected to an initial rigid body refinement in X-PLOR (25),
where 
 
a
 
1
 
a
 
2, 
 
a
 
3, and 
 
b
 
2
 
m were treated as individual domains.
After two rounds of manual rebuilding in O (26) and refinement
in X-PLOR, which involved simulated annealing with bulk sol-
vent correction, clear electron density appeared in the 3Fo-2Fc
map for the peptide region, including all of the side chains of the
peptide. Subsequent refinement used the maximum likelihood
method implemented in crystallography and nuclear magnetic res-
onance system (CNS) (27). The minimization procedure included
positional refinement and simulated annealing with bulk solvent
correction and initial overall anisotropic B factor correction, fol-
lowed by group B factor refinement. The final model contains res-
idues A2–274 of the heavy chain, B0–98 of 
 
b
 
2
 
m (B0 corresponds
to the initial methionine that was engineered for expression in
 
E
 
.
 
 coli
 
), P1–9 of the peptide, and 35 water molecules (Table I). The
35 water molecules were selected and refined based on peaks that
were at least 2.0 
 
s
 
 in height in Fo-Fc and 3Fo-2Fc electron density
maps. All 
 
f
 
 and 
 
c
 
 angles lie in the allowed regions of the Ra-
machandran plot, with 86% in the most favorable regions. The
NH
 
2
 
 and COOH termini of the heavy chain (A1 and A275), as
well as the COOH terminus of 
 
b
 
2
 
m (B99), have no visible elec-
tron density. Side chains for residues A104–108 and A195–198 in
the loop region of the heavy chain and residues B17–19 of 
 
b
 
2
 
m
have weak electron densities and B factors 
 
.
 
80 Å
 
2
 
.
 
Table I.
 
Statistics for Data Collection and Refinement
 
Data collection
Resolution (Å) 22–2.9 3.0–2.9
Unique reflections 10,533 995
Unique reflections (
 
.
 
3 
 
s
 
) 9,849 804
Completeness (%) 97.9 96.9
Redundancy 5 4
 
R
 
sym
 
 (%)
 
*
 
11.2 32.3
Refinement (22–2.9 Å)
No. reflections 9,448
No. reflections (
 
R
 
free
 
 set)
 
§
 
1,085
 
R
 
cryst
 
 (%)
 
‡
 
21.6
 
R
 
free
 
 (%)
 
§
 
27.1
Nonhydrogen protein atoms 3,144
Water molecules 35
Average B factors (Å
 
2
 
) 49.7
Root mean square deviations
Bonds (Å) 0.008
Angles (°) 1.70
B factors (Å
 
2
 
) 2.5
Estimated coordinate error (Å)
 
i
 
0.33
Ramachandran plot statistics (%)
Residues in most favored regions 85.8
Residues in additional allowed regions 13.0
Residues in generously allowed regions 1.2
Residues in disallowed regions 0.0
 
*
 
R
 
sym
 
 
 
5 
 
(
 
å
 
u
 
I
 
(
 
i
 
) 
 
2
 
 <
 
I
 
>|)/(
 
å
 
I
 
(
 
i
 
)), where 
 
I
 
(
 
i
 
) is the intensity of an indi-
vidual reflection and <
 
I
 
> is the average intensity of that reflection.
 
‡
 
R
 
cryst
 
 
 
5
 
 (
 
å
 
i
 
Fo
 
u 
 
2
 
 
 
u
 
Fc
 
i
 
)/(
 
å
 
u
 
Fo
 
u
 
), where Fo and Fc are the observed
and calculated structure factor amplitudes.
 
§
 
R
 
free
 
 is equivalent to 
 
R
 
cryst
 
 but calculated for a randomly chosen 10% of
reflections that were omitted from the refinement process.
 
i
 
Coordinate error is estimated from the Luzzati plot in CNS (70). 
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Results
 
Overall Structure of the Consensus Peptide–HLA-Cw4
Complex.
 
The ectodomain of the HLA-Cw4 heavy
chain  was overexpressed as inclusion bodies in 
 
E
 
. 
 
coli
 
 and
reconstituted in the presence of 
 
b
 
2
 
m and a nonameric
peptide (QYDDAVYKL) that contains the consensus pep-
tide binding motif for HLA-Cw4 (21, 28, 29). The con-
sensus peptide motif was determined by pool sequencing
and included an aromatic residue or proline for P2, a hydro-
phobic COOH-terminal anchor, a hydrophobic auxiliary
anchor at P6, and the frequent use of glutamic acid and as-
partic acid at P4 (29). Refolded HLA-Cw4 binds directly
to KIR2DL1, as shown by a native gel shift assay (21). The
crystal structure of HLA-Cw4 was determined by molecu-
lar replacement, using HLA-B27 (24) as the search model,
and refined at 2.9 Å (
 
R
 
cryst
 
 5 
 
21.6%;
 
 R
 
free
 
 5 
 
27.1%). The
final model contains heavy chain residues A2–274, 
 
b
 
2
 
m
residues B0–98, peptide residues P1–9, and 35 water mol-
ecules. The loop regions at residues A104–108 and A195–
198 in the heavy chain and residues B17–19 in 
 
b
 
2
 
m have
weak electron density and high B factors (
 
.
 
80 Å
 
2
 
), indicat-
ing that these regions are disordered. Clear electron density
is observed for the entire peptide (Fig. 1).
The overall structure of HLA-Cw4 is similar to that of
HLA-A and -B molecules (24, 30–34), as expected from
the high sequence homology (
 
z
 
85% sequence identity)
among HLA-A, -B, and -C heavy chains. The root mean
square (rms) deviation between HLA-Cw4 and HLA-A2 is
0.8 Å for 368 C
 
a
 
 atoms, and the rms between HLA-Cw4
and B53 is 0.8 Å for 380 C
 
a
 
 atoms. (HLA-A2 [2.5 Å] and
-B53 [2.3 Å] are chosen for comparison because the struc-
tures of these molecules bound to single nonameric pep-
tides are available at high resolution.) The structure differ-
ences among HLA-A, -B, and -C molecules are due to the
relative orientations of the individual 
 
a
 
1
 
a
 
2, 
 
a
 
3, and 
 
b
 
2
 
m
domains. The 
 
a
 
1
 
a
 
2 domains of HLA-Cw4 and HLA-A2
can be superimposed with an rms deviation of only 0.6 Å
for 172 C
 
a
 
 atoms. As shown in Fig. 2 a, when the 
 
a
 
1
 
a
 
2
domains of HLA-Cw4 and HLA-A2 are superimposed, the
a3 domain adopts a different position relative to a1a2 in
each structure.
In the a1a2 domain, the structure of HLA-Cw4 differs
from many human and mouse class I MHC structures near
the COOH-terminal portion of the a1 helix (residues
A67–77), widening the peptide binding groove in this re-
gion by up to 2.4 Å in comparison with HLA-A2 (refer-
ence 32; Fig. 2 b). HLA-Cw4 also differs dramatically (up
to 4.2-Å shift in Ca atom positions) from HLA-A2 in the
loop region connecting S1 and S2 of the a1 domain b sheet
(residues A14–20) (Fig. 2 b). Relative to HLA-A2, the S1-S2
loop protrudes up and toward the a1 helix (Fig. 2 a). As a
result, Arg17 in HLA-Cw4 partially replaces Arg14 found
in HLA-A2 in forming a hydrogen bond with Glu19 and a
salt bridge to Asp39 (not shown). Furthermore, two salt
bridges between Glu19 in the loop and Arg75 on the a1
helix are lost. As the S1-S2 loop is involved in crystal pack-
ing and may be an artifact, the biological significance of the
loop difference remains to be explored. Other regions in
the a1a2 domain that differ between HLA-Cw4 and
HLA-A2 include the loop connecting S3 and S4 of the a1
domain b sheet (residues A38–45, up to 2.8-Å difference
in Ca positions) (Fig. 2 b). The COOH-terminal end of
the a1 helix is implicated in HLA-C recognition by KIR
(for review see references 9 and 10). The a2 helix has been
observed to affect binding of Ly-49 to mouse class I MHC
molecules (35–37). It is unknown whether the a2 helix
may also participate in the KIR–HLA-C interaction. The
COOH-terminal end of the a1 helix, together with its
adjacent loop region, may define a KIR binding site on
HLA-C that is different from the Ly-49 binding site on
mouse class I MHC molecules.
Figure 1. 2Fo-Fc simulated anneal-
ing omit electron density map of
HLA-Cw4 contoured at 1.0 s and in
the region of the peptide (displayed in
O with a map cover radius of 1.0 Å)
(26). Peptide residues and positions are
labeled, QYDDAVYKL.116 HLA-Cw4 Structure
The a3 and b2m domains of HLA-Cw4 are very similar
to those of HLA-A2. One of the regions that varies among
the different HLA molecules in the a3 domain is the loop
consisting of the acidic residues A223–229. Similar to other
class I MHC molecules, residues A225–227 in HLA-Cw4
form a turn of 310 helix. The loop is involved in the bind-
ing of CD8 to class I MHC (38).
Extensive Peptide–HLA-Cw4 Interactions along the Peptide
Result in Large Buried Surface Area. Structures of HLA-A and
-B have demonstrated that the ends of the peptides (P1–P2,
P8–P9) are similarly bound in the cleft through con-
served hydrogen bonds, whereas the structural variations
occur in the central portion of the peptides. Fig. 2 c com-
pares the conformation of peptides bound to HLA-Cw4
(QYDDAVYKL), HLA-A2 (Tax peptide, LLFGYPVYV;
reference 32), and HLA-B53 (epitope gag peptide from
HIV2, TPYDINQML; reference 33). As in other HLA
structures, the peptide termini in HLA-Cw4 are anchored
in the cleft by a number of contacts between the peptide
main chain atoms and conserved MHC side chains (Table II;
Fig. 3 a). At the NH2 terminus, the P1Gln main chain atoms
hydrogen-bond to three tyrosine residues from HLA-Cw4
(Tyr7, 159, and 171). A hydrogen bond between the main
chain NH2 group of P2Tyr and the side chain carboxylate
of Glu63, which is observed in HLA-A2 and -B27 but ab-
sent in HLA-B53, is found in the HLA-Cw4 structure.
The conserved hydrogen bonds at the COOH terminus in-
clude the ones from the terminal carboxylate oxygen of
P9Leu to the side chains of Thr143 and Lys146. The in-
variant hydrogen bond from the carbonyl oxygen at P8Lys
to the pyrrole nitrogen of Trp147 is also present. In addi-
tion to the conserved hydrogen bonding network found at
the peptide termini, extensive interactions also occur be-
tween HLA-Cw4 and the central portion of the peptide.
For peptide residues P2–P8, there are five hydrogen bonds
from the peptide main chain to HLA-Cw4 side chain at-
oms and two from the peptide side chain to HLA-Cw4
side chain atoms. We have not been able to observe any
water molecule in the region of the peptide, probably due
to the limitation of the resolution.
The solvent-accessible surface area buried upon peptide
binding for HLA-Cw4 is greater than that found in most
peptide–MHC complexes. In the case of HLA-A2 bound
to the Tax peptide (LLFGYPVYV), the total solvent-acces-
sible area buried is 1,723 Å2 (calculated using the program
SURFACE, reference 39; probe radius, 1.4 Å); for HLA-
B53 bound to the gag epitope of HIV2 (TPYDINQML),
the area buried is 1,647 Å2. In contrast, a total 1,914 Å2 of
solvent-accessible surface area is buried (1,109 Å2 on the
peptide and 805 Å2 on the MHC heavy chain) upon peptide
binding to HLA-Cw4. As shown by the plot in Fig. 4,
the three NH2-terminal residues (P1–P3) and the COOH-
terminal residue (P9) of the HLA-Cw4 peptide are almost
completely buried (with .93% of the surface area buried for
each residue). The two residues in the central region that are
mostly exposed are P4Asp and P8Lys. P4Asp is the highest
point of the peptide; together, P4Asp and P3Asp form the
kink in the peptide main chain conformation that has been
Figure 2. (a) Ca traces of HLA-
Cw4 (red) and HLA-A2 (blue) (RIB-
BONS; reference 69). The a1a2 do-
mains of the two structures have been
superimposed. The positions of the
a3 and b2m domains vary in each
structure. (b) Top view of the super-
imposed a1a2 domains of HLA-Cw4
(red) and HLA-A2 (blue). HLA-Cw4
and HLA-A2 differ significantly at the
COOH-terminal end of the a1 helix
(A67–77) and in the adjacent loop re-
gions (A14–20 and A38–45). The
eight  b strands are marked S1–S8. (c)
Stereo view of the superposition of
the peptides bound to HLA-Cw4
(QYDDAVYKL, red), HLA-A2 (Tax
peptide, LLFGYPVYV, blue) and
HLA-B53 (gag peptide from HIV2,
TPYDINQML, green). The pep-
tides are brought into superposition
by superimposing the a1a2 domains
of the HLA-Cw4, -A2, and -B53
heavy chains. The peptides are
viewed from the side as they lie in the
peptide binding groove.117 Fan and Wiley
observed for many known structures of peptides bound to
class I MHC molecules. P8Lys, on the other hand, has been
implicated in the binding of HLA-Cw4 to KIR (40).
Internal Hydrogen Bonding of Peptide Stabilizes the Confor-
mation of the HLA-Cw4–Bound Peptide. The HLA-Cw4
structure differs from most known structures of class I MHC
molecules in that the peptide conformation includes a pat-
tern of internal hydrogen bonding within the peptide (Fig.
3 b). The main chain–main chain hydrogen bond between
the carbonyl oxygen of P2Tyr and the NH2 group of
P4Asp causes P4Asp to adopt f and c angles that are found
in a left-handed helix and usually observed in residues
forming tight turns and kinks (f 5 73.88, c 5 18.28). All
other residues of the peptide have f and c angles that are
typical for an extended b strand. In addition, two hydrogen
bonds are also formed between a side chain carboxylate ox-
ygen atom of P3Asp and the main chain amino groups of
P4Asp and P5Ala. The side chain of P3Asp can not fit into
a small D pocket (41) underneath the a2 helix and formed
by the side chains of Arg97, Phe99, Arg156, and Tyr159
(Fig. 5 c). As a result, although the Cb atom of P3Asp
points toward the a2 helix, its side chain carboxylate is
turned back toward the peptide, forming hydrogen bonds
with the peptide main chain atoms and the side chain atoms
of Arg156 (Fig. 3 b; Table II). An internal hydrogen-bonded
type I turn has previously been identified in the structure of
an HIV gp120 peptide bound to murine H-2Dd (42, 43).
P3Asp and P4Asp are important for the binding of the
consensus peptide to HLA-Cw4. A peptide containing a
single amino acid substitution from P3Asp®P3Ala fails to
increase the level of assembled HLA-Cw4 on the surface of
the TAP-deficient RMA-S cells that are transfected with
the HLA-Cw4 cDNA and human b2m (40). The P3Asp®
P3Ala mutation results in the loss of three hydrogen bonds
mediated by the P3Asp side chain, two internal hydrogen
bonds and one hydrogen bond with the side chain of
Arg156. Substituting P3Asp and P4Asp with P3His and
P4Pro also abolishes peptide binding to the cleft (40).
These substitutions would have eliminated all of the inter-
nal hydrogen bonds that stabilize the peptide conformation.
The side chain of P3His would not be able to fit into the
small D pocket, which remains unoccupied even in the
case of a smaller side chain of P3Asp. Furthermore, elec-
tronic repulsion between the side chains of Arg97, Arg156,
and P3His would have greatly destabilized the peptide–
MHC complex.
Four Specificity Pockets Explain the Sequence Motif of HLA-
Cw4–specific Peptides. The HLA-Cw4 peptide binding
groove is characterized by four specificity pockets (Fig. 5, a
and b). The P1 pocket forms the NH2-terminal boundary
of the peptide binding groove and is located in the region
of the A pocket (41). The peptide binding groove is com-
pletely blocked at this end by the residues Arg62 and
Trp167, which point toward each other across the cleft
(not shown). The P1 pocket includes the highly conserved
tyrosine residues 7, 159, and 171, which hydrogen-bond to
the peptide NH2 terminus (Fig. 3 a). As in HLA-A2, the
pocket is lined with the rather polar residues Tyr59, Glu63,
Lys66, Tyr159, Thr163, Cys164, and Tyr171, and its floor
is formed by Met5 and Tyr7. The P1Gln side chain is
firmly positioned by two hydrogen bonds from its side
chain amide group to Glu63 and Lys66. Substitution of
P1Gln by P1Ser induces a similar level of HLA-Cw4 ex-
pression on the cell surface (40), indicating that the P1
pocket is accommodating to medium sized polar residues.
The HLA-Cw4 structure possesses a P2 pocket that is
highly specific for tyrosine. The P2 pocket is formed by a
cluster of aromatic residues, including Tyr7, Phe22, Tyr67,
and Phe99. The hydroxyl group of P2Tyr points toward two
polar residues, Arg97 and Gln70, which separate the P2
pocket from the neighboring P7 pocket. The P2 pocket is
rather spacious and is not completely filled even by the bulky
side chain of P2Tyr. It is conceivable that with minor adjust-
ments, a water molecule could bridge the interaction be-
tween the hydroxyl group of P2Tyr and the polar side chains
of Arg97 and Gln70. The role of water molecules in mediat-
ing the interaction between the peptide and the cleft has been
observed in the structures of both human and mouse class I
MHC molecules, including HLA-B53, HLA-B27, H-2Kb,
H-2Db, H-2Dd, and H2-M3 (24, 33, 42, 44–46).
Table II. Peptide Hydrogen Bonds to HLA-Cw4
Peptide
Hydrogen
bond partner
Distance Residue Atom Residue Atom
Å
P1Gln N Tyr7 OH 3.0
N Tyr171 OH 2.8
Ne2 Glu63 Oe1 3.1
Oe1 Lys66 Nz 2.9
O Tyr159 OH 2.6
P2Tyr N Glu63 Oe2 2.7
O Lys66 Nz 3.0
O P4Asp* N 3.2
P3Asp Od1 P4Asp* N 3.1
Od1 P5Ala* N 2.9
Od2 Arg156 N 3.0
P5Ala O Arg156 Nh1 3.2
P6Val O Arg156 Nh2 3.2
P7Tyr OH Asp74 Od1 3.1
OH Asp74 Od2 2.9
P8Lys O Trp147 Ne1 2.8
P9Leu N Asn77 Od1 2.8
O Lys146 Nz 3.2
O Thr143 Og1 3.1
Hydrogen bonds (,3.2 Å, generated in O; reference 1) from peptide
residues QYDDAVYKL to HLA-Cw4.
*Internal hydrogen bonds between peptide residues. All other residues
that form hydrogen bonds with the peptide belong to the HLA-Cw4
heavy chain.118 HLA-Cw4 Structure
Proline was identified by pool sequencing to be an alter-
native anchor residue at P2 for HLA-Cw4 (29). Cellular
binding assays indicate that substitution of P2Tyr with
P2Pro abolishes peptide binding to cell-surface HLA-Cw4
(40). The structure of HLA-Cw4 also predicts that proline
at P2 would be destabilizing. Substitution of P2Tyr with
P2Pro would eliminate the hydrogen bond from the main
chain amino group of P2 to the side chain carboxylate ox-
ygen of Glu63 and leave the entire P2 pocket vacant. It is
possible that the pool sequencing signal for P2Pro was due
to the low levels of HLA-B35 expressed on the surfaces of
the cells used for pool sequencing.
One of the distinct features of HLA-Cw4 is a P7 pocket
located on the side of the a1 helix, formed mostly by resi-
dues from the a1 helix (Gln70, Asp74, and Asn77) and the
b sheet platform (Ser9, Phe22, Leu95, Arg97, and Phe116).
The P7Tyr side chain is secured in the specificity pocket by
two hydrogen bonds from the P7Tyr hydroxyl group to
the carboxylate oxygen atoms of Asp74. In the known
structures of nonameric peptide–MHC complexes, the P5
and P7 side chains are generally oriented toward the a2 he-
lix, whereas the P4 and P6 side chains point toward the a1
helix (32). A well-defined P7 pocket has not been observed
in HLA-A and -B structures. In the structure of HLA-E
bound to a nonamer derived from the signal peptide of
HLA-B8 (47), P7 side chain fills a single pocket down to-
ward the a2 helix, which coincides with the E pocket
identified by Saper et al. (41). In HLA-Cw4, the Cb atom
of the P7Tyr residue points toward the a2 helix; however,
the large side chain of Arg156 forces the P7 side chain to
turn and point its phenyl ring toward the a1 helix. The P7
pocket in HLA-Cw4 is at the location of the C pocket
(41). The presence of Asp9 and Ala73 in the C pocket of
some HLA-C alleles has been linked to increased suscepti-
bility to psoriasis vulgaris (48, 49). The distinct features of
the C pocket in HLA-Cw4 may also be important in its as-
sociation with type 2 diabetes (7).
The C pocket in HLA-Cw4 is adjacent to the B pocket
Figure 3. (a) Stereo diagram of the hydrogen bonds formed between
the peptide and HLA-Cw4 cleft (RIBBONS; reference 69). Conserved
hydrogen bonds are represented by black dashed lines, and the other hy-
drogen bonds are in light gray. The residues from HLA-Cw4 are colored
dark gray. The peptide is in yellow. (b) Internal hydrogen bonds formed
within HLA-Cw4–bound peptide.
Figure 4. Solvent-accessible surface area buried for the peptide. Sol-
vent-accessible surface area buried upon HLA-Cw4 binding is calculated
for each residue of the peptide (QYDDAVYKL), using probe radius of
1.4 Å (SURFACE; reference 39).119 Fan and Wiley
that hosts the P2 side chain and is separated from the B
pocket by a polar ridge formed by the side chains of Ser9,
Arg97, and Gln70 (Fig. 5 a). A mouse-specific hydropho-
bic ridge formed by Trp73, Tyr156, and Trp147 has been
found in H-2Db and H-2Ld (45, 50, 51). A tryptophan wall
created by residues Trp97 and Trp114 is located in the
middle of the H-2Dd cleft (42).
The P9 pocket at the COOH-terminal end of the pep-
tide binding groove is hydrophobic, formed by the side chains
of Leu81, Leu95, Phe116, Tyr123, Ile124, and Trp147.
The pocket forms the COOH-terminal boundary of the
cleft. The pocket is not completely filled by the side chain
of P9Leu. It can host an even larger hydrophobic residue,
such as phenylalanine. Hydrophobic PV pocket is charac-
teristic of HLA-A2, HLA-E, and all known mouse class I
MHC structures (30, 41, 42, 44, 45, 47, 50, 52).
KIR Binding Site on HLA-Cw4: Electrostatic Interactions
Mediate the Binding of KIR2DL1 to HLA-Cw4. The KIR
binding site on HLA-C is located on the a1 domain and
includes residues 73, 76, 77, and 80 at the COOH-terminal
end of the a1 helix and residue 90 on the loop following it
in sequence (14, 53–56). Studies of the KIR3D receptors
(e.g., NKB1) that specifically recognize the HLA-Bw4
family indicate that the same region, residues 77–83 in the
a1 domain of HLA-B molecules, participates in the inter-
actions with KIR (53, 57). Peptide residues P7 and P8 have
also been observed to affect the binding of KIRs to HLA-C
and -B molecules (40, 58–60).
In HLA-Cw4, the region surrounding the COOH-ter-
minal end of the a1 helix and residue P8 of the peptide has
an electropositive polar surface (Fig. 6 c, blue). The elbow
region of KIR2DL1 contains residues involved in HLA-C
binding (Met44, Phe45, and Thr70) (18–20, 61); it has an
electronegative polar surface (Fig. 6 e, red). The ligand
binding site on KIR2DL1 and the receptor binding site on
HLA-Cw4 are complementary in their polarity, and recog-
nition of HLA-Cw4 by KIR2DL1 is possibly mediated by
the polar interactions between the oppositely charged sur-
faces on the two molecules.
Among the residues implicated in KIR binding, residue
80 on HLA-C molecules determines the specificity of HLA-
Cw4 for KIR2DL1 and, similarly, that of HLA-Cw3 for
KIR2DL3 (55). The structure of HLA-Cw4 confirms the
importance of residue 80 in mediating the interaction be-
tween HLA-C and KIR2D. As shown in Fig. 6 a, the resi-
dues that differ between HLA-Cw4 and HLA-Cw3 are
concentrated along the peptide binding groove. Once the
peptide is bound, however, many of the residues, including
residue 77, are buried in their interactions with the peptide
(Fig. 6 b). Residue 80 is highly exposed and located at the
center of the electropositive surface on HLA-Cw4 that
forms the potential KIR binding site (Fig. 6, b and c).
HLA-Cw4 loaded with peptides containing the nega-
tively charged glutamic acid or aspartic acid at P8 are not
recognized by a KIR2DL1–Ig fusion protein (40). Peptide
residue P8 is important for KIR binding, partly due to the
fact that P8 is highly exposed (with 68% of its surface area
exposed), with its side chain forming a protrusion on the
HLA-Cw4 surface (Fig. 6, b and c). As the P8Lys protru-
sion is one of the highest points on the HLA-Cw4 surface,
it will be readily contacted by KIR2DL1 that approaches
HLA-Cw4 from the top of the Cw4 cleft. The positively
charged P8Lys in the consensus peptide contributes greatly
to the electropositive surface around the COOH-terminal
end of the a1 helix. The negatively charged glutamic acid
or aspartic acid side chain would result in electronic repul-
sion between the electronegative surface at the KIR2DL1
elbow and the P8 residue of HLA-Cw4 peptide, thereby
abolishing receptor–ligand binding.
A single substitution of tyrosine by glutamic acid at P7 in
the peptide also disrupts the interaction between KIR2DL1
and HLA-Cw4 (40). The P7 side chain is buried in a pocket
under the a1 helix (compare Figs. 6 a and b). The P7 pocket
is acidic, formed in part by the residues Gln70, Asp74, and
Asn77. Charge–charge repulsion between the P7Glu side
chain and the acidic pocket would destabilize the structure.
The effect of the P7 residue on the binding of KIR to HLA-
Cw4 is likely to be mediated through the conformational
changes of the peptide main chain a1 and a2 helices that are
necessary to accommodate the P7 side chain.
The specificity of HLA-Cw4 and KIR2DL1 interaction is
also mediated by hydrophobic interactions. As shown by Fig.
6 d, residues that differ between KIR2DL1 and KIR2DL2
form hydrophobic patches adjacent to the electronegative
Figure 5. (a) Electropotential molecular surface (GRASP; reference 70) of the peptide
binding groove of HLA-Cw4, illustrating the four specificity pockets. The surface is colored
according to its potential charge: red, negatively charged and blue, positively charged, with a
scale from 213 to 113 kT. (b) Molecular surface representation of HLA-Cw4, with a ball
and stick model of the peptide. (c) P3 pocket as viewed from the side of the peptide groove.120 HLA-Cw4 Structure
surface at the KIR2DL1 elbow (Fig. 6 e). Among these res-
idues, Met44 determines the specificity of KIR2DL1 for
HLA-Cw4 (18), and Thr70 affects their binding affinity
(20). A single mutation from Met44 in KIR2DL1 to Lys44
found in KIR2DL2 switches the specificity of KIR2DL1
from HLA-Cw4 to HLA-Cw3. Lys44 may disrupt the hy-
drophobic interactions mediated by Met44. Furthermore,
its electropositive side chain may be repelled by the elec-
tropositive surface on HLA-Cw4.
Discussion
The structure of HLA-Cw4 allows us to predict the
structural features of the closely related HLA-Cw3 mole-
cule. First, HLA-Cw3 and HLA-Cw4 have different speci-
ficities for the P2 pocket. The residues that line the P2
pocket include Ser9 and Phe99 in HLA-Cw4 but Tyr9 and
Tyr99 in HLA-Cw3. These large side chains found in
HLA-Cw3, if oriented like those in HLA-Cw4, would re-
duce the size of the P2 pocket and preclude any bulky side
chain for the P2 residue. This structural argument is consis-
tent with pool sequencing results, which indicate that the
dominant signal for P2 in HLA-Cw3 is alanine (29).
Unlike most known class I MHC structures that possess a
P7 pocket coincident with the E pocket under the a2 he-
lix, the HLA-Cw4 structure reveals a P7 pocket on the side
of the a1 helix. The P7 pocket in HLA-Cw4 is located in
the same area as the C pocket identified by Saper et al. (41).
The side chain of P7Tyr in HLA-Cw4 fits into a pocket
adjacent to that for P2, partly because the internal hydro-
gen bonds cause the peptide residues from P4 to P7 to shift
toward its NH2 terminus (up to 1.1 Å) and deeper into the
cleft (up to 1.6 Å) relative to the Tax peptide bound to
HLA-A2. The HLA-Cw3–specific peptides do not contain
a P3Asp, which is crucial in forming the internal hydrogen
bonds within the HLA-Cw4–bound peptide. Peptides
bound to HLA-Cw3 therefore are more likely to adopt
conformations similar to those found in HLA-A and -B
peptides. In particular, there is not likely to be a shift of the
central part of the peptide (P4–P7) toward the peptide
NH2 terminus. The large side chain of Arg156 precludes a
P7 pocket on the side of the a2 helix in HLA-Cw4. In
HLA-Cw3, Arg156 is substituted with the smaller residue
Leu156, creating a P7 pocket in the area of the E pocket
under the a2 helix. Instead of tyrosine at P7 for HLA-Cw4,
pool sequencing indicates that HLA-Cw3 has a strong sig-
Figure 6. Molecular surface representation of
HLA-Cw4 (a, b, and c) and KIR2DL1 (originally
named p58-cl42 KIR; d and e) (GRASP; refer-
ence 70). (a) The molecular surface is colored
according to the sequence variation between
HLA-Cw4 and HLA-Cw3. Residues that differ
between HLA-Cw4 and HLA-Cw3 are colored
green. The peptide is omitted from the surface
calculation. (b) As in panel a, green represents res-
idues that differ between HLA-Cw4 and HLA-
Cw3; magenta marks the residues of the peptide
(QYDDAVYKL). The molecular surface is calcu-
lated for the entire peptide–MHC complex. (c)
The electropotential molecular surface is calcu-
lated for the entire peptide–MHC complex, using
the same scale as in Fig. 5. The molecular surface
of HLA-Cw4 in a, b, and c is viewed from the
same orientation in a, b, and c, that is, from the top of the peptide binding groove. Residues from the a1 domain are labeled in brown, whereas those
from the a2 domain are labeled in black. Peptide residues are marked in red. (d) The molecular surface is colored according to the sequence variation be-
tween KIR2DL1 (specific for HLA-Cw4) and KIR2DL2 (specific for HLA-Cw3). Residues that differ between KIR2DL1 and KIR2DL2 are marked
green. (e) The molecular surface is colored according to its potential charge as in c. Arrows point to acidic residues that are located at the domain elbow
and form the electronegative polar surface. (These acidic residues include Asp 72, 135, and 183 and Glu187.) The molecular surface of KIR2DL1 is
viewed from the same orientation in d and e, that is, facing the domain elbow between D1 and D2. Residues in D1 are labeled in brown, whereas those
in D2 are marked black.121 Fan and Wiley
nal for phenylalanine or tyrosine at P6. As the residues that
form the C pocket are conserved between HLA-Cw4 and
HLA-Cw3, it is possible that the C pocket is filled with the
aromatic side chain of P6 in HLA-Cw3.
In the structure of the human TCR–HLA-A2 complex
(62, 63), two different TCRs contact the entire length of the
bound peptide (residues P1, P2, and P4–P8). The sequence
and conformation of antigenic peptide determines the speci-
ficity of the T cell recognition. In mice, the extensive in-
teraction between the TCR and the peptide across the cleft
is observed in the structures of the mouse TCR 2C–H-2Kb
and TCR N15–H-2Kb complexes (64–66). Unlike the case
with T cells, which are activated by viral antigens presented
on class I MHC molecules, recognition of properly pro-
cessed self class I MHC–peptide assembly by KIR inhibits
target cell lysis by NK cells. In mice, Ly-491 NK cells bind
to assembled peptide–class I MHC complexes, but a di-
verse array of peptides are capable of inducing inhibition
(67), indicating that Ly-49 recognition of mouse class I
MHC is peptide independent. In humans, both KIR2D and
KIR3D contact the COOH-terminal end of the a1 helix
(for review see references 9 and 10). Peptides also play a role
in the recognition of the HLA-B and -C molecules; peptide
residues P7 and P8 appear to affect the binding of KIR to
class I MHC molecules directly (40, 58–60). For HLA-Cw4,
negatively charged residues at P7 and P8 of the peptide abol-
ish HLA-Cw4–KIR2DL1 binding (40). For HLA-Cw3,
two different peptides confer protection of Cw3-bearing tar-
get cells from P58.21 NK cells (68). For HLA-B27, two NK
cell clones discriminate among HLA-B27 loaded with four
different peptides (59). Therefore, NK cell recognition of
class I MHC molecules in humans is peptide dependent but
not as specific as T cell recognition, as a much more diverse
collection of peptides can confer protection.
The structure of HLA-Cw4 reveals features that may be
involved in the recognition of the class I MHC molecule
by KIR2DL1. The specific interaction of the receptor–
ligand pair appears to involve complementary charged
surfaces, with the KIR binding site on HLA-Cw4 being
electropositive and the ligand binding site on KIR2DL1
electronegative. Peptide residue P8Lys contributes to spe-
cific binding in a unique way in that its side chain is ex-
posed on top of the HLA-Cw4 binding surface, forming a
projection that will inevitably be “touched” by the recep-
tor. The structural features of HLA-Cw4 that mediate its
interaction with KIR2DL1 may be conserved in the related
HLA-C allotypes that are recognized by the same inhibi-
tory NK cell receptor.
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